PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

NCT06737081 · Phase 2 · Recruiting

PHASEPhase 2
STATUSRecruiting
ENROLLMENT60
EST. COMPLETION2025-12-31

Conditions

Anemia

Interventions

SAL-0951 tablets 4mgSAL-0951 tablets 5mg

Study details

SPONSORShenzhen Salubris Pharmaceuticals Co., Ltd.
START DATE2024-09-14

Related company profiles

Shenzhen Salubris Pharmaceuticals

002294.SZ

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT06737081
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record